证券代码：688117 证券简称：圣诺生物 公告编号：2025-009 成都圣诺生物科技股份有限公司 关于2025年度申请银行综合授信额度并提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 被担保人：全资子公司成都圣诺生物制药有限公司（以下简称"圣诺制 药"），全资子公司眉山汇龙药业科技有限公司（以下简称"眉山汇龙"） 成都圣诺生物科技股份有限公司（以下简称"公司"）及子公司 2025 年度拟向银行申请不超过人民币 7.10 亿元的综合授信额度。同时，公司拟为合 并报表范围内的子公司、子公司之间提供合计不超过人民币 3.70 亿元的担保额 度，实际担保金额以最终签署并执行的担保合同或金融机构批复为准。 截至本公告披露日，公司实际为全资子公司提供的担保总额为 3.00 亿元 （不含本次担保），担保余额为 1.93 亿元，公司实际对外提供的反担保总额为 0.2 亿元（不含本次担保），反担保余额为 0.2 亿元。 本次担保不涉及反担保。 本次申请银行授信额度并提供担保事项尚需提交公司 2024 年年 ...

成都圣诺生物科技股份有限公司 2024 年度董事会审计委员会履职报告 根据《上市公司治理准则》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》《上海证券交易所科创板股票上市规则》以及《公司章程》 《审计委员会议事规则》等相关规定，成都圣诺生物科技股份有限公司（以下简 称"公司"）董事会审计委员会认真履行审计职责，积极开展审计委员会工作。 现对 2024 年度履职情况报告如下： 一、董事会审计委员会基本情况 因独立董事唐国琼女士向公司董事会申请辞去公司独立董事及董事会相关 专门委员会的职务，公司于 2024 年 1 月 15 日召开 2024 年第一次临时股东大会， 补选徐正松先生为公司第四届董事会独立董事及公司董事会审计委员会主任委 员。 公司 2024 年度第四届董事会审计委员会由徐正松先生、文发胜先生、刘霞 女士三名成员组成，其中徐正松先生、刘霞女士为公司独立董事。徐正松先生具 有会计专业资格，担任审计委员会主任委员，符合相关法律法规。 二、董事会审计委员会 2024 年度会议召开情况 报告期内，公司共召开审计委员会会议 4 次，具体召开情况如下： | 序号 | 会议名称 | 会议时间 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-008 成都圣诺生物科技股份有限公司 关于预计2025年度日常关联交易额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东大会审议：是 本次关联交易属公司日常关联交易，是以正常生产经营业务为基础，以 市场价格为定价依据，遵循公允、合理的原则，公司主营业务不会因上述交易对 关联方形成依赖，不会影响公司独立性，不存在损害公司及全体股东特别是中小 股东利益的行为。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 4 月 24 日，成都圣诺生物科技股份有限公司（以下简称"公司"） 召开第四届董事会第二十五会议、第四届监事会第二十四次会议，审议通过《关 于预计 2025 年度日常关联交易额度的议案》。该议案关联董事已回避表决，出席 会议的非关联董事、监事一致表决通过该议案，并同意提交该议案至公司 2024 年年度股东大会审议。 公司第四届董事会独立董事专门会议 2025 年第一次会议审议通过了《关于 预计 ...

圣诺生物公告，2024年营业收入为4.56亿元，同比增长4.84%。归属于上市公司股东的净利润5002.37万 元，同比下降28.88%。公司拟向全体股东每10股分派现金红利1.4元(含税)，合计拟派发现金红利 1573.86万元(含税)，占公司2024年度归属于母公司股东净利润的比例为31.46%。同时以资本公积金转增 股本方式向全体股东每10股转增4股，合计转增4496.74万股，转增后公司总股本变更为1.57亿股。 ...

Group 1 - The first quarterly report for 2025 from the Sci-Tech Innovation Board was released by Xigao Institute, marking it as the first company to disclose such results [2] - Xigao Institute reported a revenue of 207 million yuan for Q1 2025, representing a year-on-year growth of 12.1%, and a net profit of 62.97 million yuan, also up by 12.1% [2] - The overall performance of Sci-Tech Innovation Board companies in Q1 2025 shows positive signals, with 14 companies reporting earnings forecasts, including 9 with expected profit increases and 5 turning losses into profits [2] Group 2 - Linweina, the first chip testing probe company in the A-share market, achieved a revenue increase of 112% in Q1 and turned a profit due to higher sales of high-margin products and expanded sales scale [3] - Tailin Micro, a leader in low-power Bluetooth chips, reported a revenue of 230 million yuan in Q1, with a year-on-year increase of 43% and a net profit increase of approximately 894% [3] - Guanda Special Materials achieved a revenue of 1.12 billion yuan in Q1, with a net profit increase of 1504.79%, driven by strong demand in downstream industries and the effectiveness of its fundraising projects [3][4] Group 3 - Companies like United Imaging and Guoxin Technology are maintaining strong R&D momentum and practical business strategies, with United Imaging reporting over 140 product approvals globally [5] - Guoxin Technology disclosed significant progress in RISC-V architecture development, showcasing its R&D capabilities with successful internal testing of a new high-performance cloud security chip [5] - Zhongchuan Special Gas reported a 142.42% year-on-year increase in new orders for its trifluoromethanesulfonic acid series products in Q1 2025 [5] Group 4 - A total of 33 share repurchase plans have been disclosed on the Sci-Tech Innovation Board in 2025, with a maximum repurchase amount of 3.215 billion yuan [6] - Companies like Daotong Technology and Zhongwulian have announced share repurchase plans, reflecting confidence in their development [6] - Key figures in the integrated circuit and new energy sectors are actively increasing their shareholdings, indicating a commitment to the future value of their companies [6]

数据显示，2021年至2023年，公司实现营业收入分别为3.87亿元、3.96亿元、4.35亿元，同比增长 2.05%、2.38%、9.93%；归母净利润分别为6125万元、6449万元、7034万元，同比增长2.09%、5.28%、 9.08%。2024年，公司实现营业总收入4.55亿元，较上年同期增长4.67%；尽管归属于母公司股东的净利 润为5473.63万元，同比下降22.18%，但这主要受到研发投入增加、集采降价传导和海外扩张成本上升 等因素的影响，公司依然在多肽药物领域保持了较强的市场竞争力。 2025年一季度，公司多肽原料药业务继续发力，销售收入实现同比大幅增长，成为公司业绩增长的主要 驱动力。3月30日，公司公告称，预计2025年一季度归属于上市公司股东的净利润为3919.85万至4790.92 万元，同比增长137.97%至190.85%；扣除非经常性损益后的净利润为3983.96万至4869.29万元，同比增 长160.62%至218.54%。 完善海外市场布局 圣诺生物近年来持续加大产能扩建力度，多个募投项目正稳步推进。 多肽类创新药公司圣诺生物（688117.SH）业绩迎来大幅增长。 ...

Core Viewpoint - Shengnuo Biotech (688117) experienced a significant stock price increase due to its strong Q1 2025 earnings forecast, with a projected net profit increase of 137.97% to 190.85% year-on-year [1] Company Summary - Shengnuo Biotech specializes in the research and development of peptide-based innovative drugs, providing pharmaceutical research and custom production services, as well as developing and selling peptide generic drugs and production technology transfer services [1] - The company reported a projected net profit for Q1 2025 between 39.19 million to 47.91 million yuan, marking a year-on-year increase of 22.73 million to 31.44 million yuan [1] - Shengnuo Biotech's peptide raw material business saw significant sales growth in Q1 2025, contributing to the overall performance increase [1] Industry Summary - Peptide drugs, known for their higher activity and selectivity compared to small molecule drugs, have been gaining traction in treating complex diseases [2] - The global peptide drug market has been steadily growing, with China's peptide drug market also on the rise [2] - Shengnuo Biotech has developed 19 self-researched peptide raw material varieties, with several products receiving production approvals in both domestic and international markets [2] - Competitors like Nuotai Biotech and WuXi AppTec are also reporting strong growth in their peptide-related businesses, indicating a competitive and expanding market [3]

Group 1 - The company expects a net profit attributable to shareholders of the parent company for Q1 2025 to be between 39.1985 million yuan and 55.000 million yuan, representing an increase of 137.97% to 190.85% compared to the same period last year [1][2] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 39.8396 million yuan and 48.6929 million yuan, which is an increase of 160.62% to 218.54% year-on-year [1][2] - The company reported a net profit of 16.4722 million yuan for the same period last year, with a net profit of 15.2864 million yuan after deducting non-recurring gains and losses [1][2] Group 2 - The significant increase in performance is attributed to the company's alignment with the development trends in the peptide industry and the expansion of its domestic and international marketing efforts, leading to substantial growth in sales revenue from peptide raw materials in Q1 2025 [2]

Financial Performance Expectations - The company expects a net profit attributable to shareholders of the parent company for Q1 2025 to be between 39.1985 million and 47.9092 million yuan, representing a year-on-year increase of 137.97% to 190.85%[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 39.8396 million and 48.6929 million yuan, an increase of 160.62% to 218.54% year-on-year[3]. - The net profit for the same period last year was 16.4722 million yuan, with a net profit of 15.2864 million yuan after deducting non-recurring gains and losses[5]. Business Growth Factors - The significant increase in performance is attributed to the company's expansion in the peptide raw material drug business, which saw substantial sales growth in Q1 2025[6]. Earnings Forecast Reliability - The company has not identified any major uncertainties that could affect the accuracy of this earnings forecast[8]. - The earnings forecast is based on preliminary calculations by the company's financial department and has not yet been audited by certified public accountants[4]. - Investors are advised that the above forecast data is preliminary and the accurate financial data will be disclosed in the official Q1 2025 report[9].

Financial Performance - The company achieved total operating revenue of RMB 455.34 million, an increase of 4.67% compared to the previous year[3] - The net profit attributable to the parent company was RMB 54.74 million, a decrease of 22.18% year-on-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 49.95 million, down 17.04% from the previous year[3] - Basic earnings per share decreased to RMB 0.49, down 22.22% from the previous year[3] - The weighted average return on net assets was 6.10%, a decrease of 2.15 percentage points compared to the previous year[3] Assets and Equity - Total assets at the end of 2024 reached RMB 1,653.75 million, reflecting a growth of 25.69% from the beginning of the period[4] - Equity attributable to the parent company increased to RMB 923.04 million, a rise of 4.90% compared to the beginning of the period[4] Business Strategy and Development - The company focused on the synergistic development of peptide drug CDMO, APIs, and formulations, leading to stable revenue growth despite increased market competition[7] - R&D expenses and financial costs increased due to the expansion of product development and production capacity, impacting net profit[7] - The company emphasizes the importance of product R&D and market expansion to enhance core competitiveness and market share[7]